Comparing to other studies using bispecific antibodies or anti-TIM3 monoclonal antibodies with the Vγ2Vδ2 T cells (7–13), our combination approach was demonstrated to be effective and safe without the additional administrations of IL2 or aminobisphoshponates or pyrophosphates for sensitizing the tumor cells. The gene discussed is IL2; the disease is neoplasm.